INmune Bio Inc (INMB)

Currency in USD
2.56
-0.23(-8.24%)
Closed·
After Hours
2.50-0.06(-2.34%)
·
INMB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
INMB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.322.60
52 wk Range
1.8911.64
Key Statistics
Prev. Close
2.79
Open
2.42
Day's Range
2.32-2.6
52 wk Range
1.89-11.64
Volume
1.32M
Average Volume (3m)
3.36M
1-Year Change
-65.22%
Book Value / Share
1.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INMB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.92
Upside
+92.19%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

INmune Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

INmune Bio Inc Company Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc Earnings Call Summary for Q2/2025

  • INmune Bio Q2 2025 EPS -$1.05, missing -$0.40 forecast; no revenue reported vs $3,000 expected; stock falls 13.26% to $2.42
  • Net loss widens to $24.5M from $9.7M YoY; $16.5M impairment charge on intangibles; cash reserves at $33.4M, supporting operations into 2026
  • CEO highlights focus on Alzheimer's, oncology, rare diseases; preparing for Cordstrom market authorization by mid-2026
  • EXPAREL FDA end-of-phase-two meeting set for Q4 2025; analysts project sales growth, price targets $0.60-$8.00 per share
  • Company faces challenges in financial sustainability, execution of partnerships, and competitive pressures in target markets
Last Updated: 08/08/2025, 11:04
Read Full Transcript

Compare INMB to Peers and Sector

Metrics to compare
INMB
Peers
Sector
Relationship
P/E Ratio
−1.2x−2.8x−0.5x
PEG Ratio
0.060.000.00
Price/Book
2.4x1.6x2.6x
Price / LTM Sales
1,361.2x214.7x3.3x
Upside (Analyst Target)
173.4%683.7%43.4%
Fair Value Upside
Unlock2.9%7.1%Unlock

Analyst Ratings

4 Buy
2 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.92
(+92.19% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-1.05 / -0.40
Revenue / Forecast
-- / 3.00K
EPS Revisions
Last 90 days

INMB Income Statement

People Also Watch

18.23
SRPT
+1.50%
51.43
BMNR
+24.59%
2.070
VOR
0.00%
5.29
REPL
-3.47%
1.48
WOLF
-1.99%

FAQ

What Stock Exchange Does INmune Bio Trade On?

INmune Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for INmune Bio?

The stock symbol for INmune Bio is "INMB."

What Is the INmune Bio Market Cap?

As of today, INmune Bio market cap is 68.06M.

What Is INmune Bio's Earnings Per Share (TTM)?

The INmune Bio EPS (TTM) is -2.52.

When Is the Next INmune Bio Earnings Date?

INmune Bio will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is INMB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has INmune Bio Stock Split?

INmune Bio has split 0 times.

How Many Employees Does INmune Bio Have?

INmune Bio has 18 employees.

What is the current trading status of INmune Bio (INMB)?

As of 10 Aug 2025, INmune Bio (INMB) is trading at a price of 2.56, with a previous close of 2.79. The stock has fluctuated within a day range of 2.32 to 2.60, while its 52-week range spans from 1.89 to 11.64.

What Is INmune Bio (INMB) Price Target According to Analysts?

The average 12-month price target for INmune Bio is USD4.92, with a high estimate of USD8 and a low estimate of USD0.6. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +92.19% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.